Concurrent Investment Advisors LLC Sells 4,226 Shares of Haleon plc (NYSE:HLN)

Concurrent Investment Advisors LLC decreased its holdings in shares of Haleon plc (NYSE:HLN) by 25.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,680 shares of the company’s stock after selling 4,226 shares during the period. Concurrent Investment Advisors LLC’s holdings in Haleon were worth $134,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of HLN. Allspring Global Investments Holdings LLC bought a new position in Haleon in the first quarter worth about $43,000. Atomi Financial Group Inc. purchased a new position in shares of Haleon in the 1st quarter valued at approximately $89,000. Sei Investments Co. boosted its position in shares of Haleon by 79.1% during the first quarter. Sei Investments Co. now owns 781,089 shares of the company’s stock valued at $6,632,000 after purchasing an additional 345,036 shares in the last quarter. QRG Capital Management Inc. grew its stake in Haleon by 8.0% in the first quarter. QRG Capital Management Inc. now owns 148,496 shares of the company’s stock worth $1,261,000 after purchasing an additional 10,973 shares during the period. Finally, Russell Investments Group Ltd. raised its holdings in Haleon by 0.3% in the first quarter. Russell Investments Group Ltd. now owns 969,627 shares of the company’s stock worth $8,232,000 after purchasing an additional 3,072 shares in the last quarter. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Analysts Set New Price Targets

HLN has been the topic of a number of recent research reports. Morgan Stanley upped their target price on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. The Goldman Sachs Group downgraded shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Berenberg Bank initiated coverage on Haleon in a research report on Tuesday, August 6th. They issued a “buy” rating on the stock. Finally, UBS Group raised Haleon to a “strong-buy” rating in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Haleon currently has an average rating of “Buy” and an average target price of $10.95.

Haleon Stock Down 2.6 %

Shares of Haleon stock opened at $9.26 on Wednesday. The company has a 50-day simple moving average of $10.16 and a two-hundred day simple moving average of $9.33. Haleon plc has a 52-week low of $7.89 and a 52-week high of $10.80. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84. The stock has a market capitalization of $41.92 billion, a PE ratio of 27.24, a price-to-earnings-growth ratio of 2.90 and a beta of 0.30.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.